Share
7,705 Posts.
lightbulb Created with Sketch. 2797
clock Created with Sketch. 13/05/21
18:29
Share
Originally posted by Silverchair:
↑
Pretty amazing half yearly results for Clinuvel, slightly more than my forecast of more than 500% profit growth and in line with my expectations for full year results of a REVENUE EXPLOSION with more than 50 % full year growth in revenue and profits. This would give Clinuvel approximate full year earnings of $46 - 50 Million Revenue and $21 - $26 Million Profits depending on costs and we know CUV tightly control costs. These sort of amazing figures are broadly in line with Pro Medicus financials which has a market cap 5 times Clinuvel of about $5 Billion so plenty of upside to the current severe CUV undervaluation. An amazing fact for CUV is they could pay a special dividend right now of $1 per share and still leave a respectable amount in the bank (about $30 Million). So in future years I see this cash generating machine actually paying out very large dividends like CSL does now, obviously the share price will be much higher then but yields for early investors (eg current prices) will be enormous and this is why I never sell CSL regardless of enormous gains. Hopefully CUV can do something similar, on a smaller scale obviously, but with the US EPP market (the worlds biggest) just at the very start of producing incomes and more growth to come from Australia, Israel, Europe, Japan and the awesome market of China we can see growth to come for many years just on this 'proof of concept' rare disease.
Expand
The patents begin to expire in 2023 and Loss Of Exclusivity (LoE) begins. That means generic Afanelanotide https://www.drugpatentwatch.com/p/tradename/SCENESSE
(20min delay)